KAF156 Antimalarial Dosing Regimen for Resistant Malaria

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current antimalarial drugs face challenges with resistance, particularly from Plasmodium falciparum, necessitating new therapies with novel mechanisms of action, and existing treatments require complex dosing regimens that can lead to non-compliance and resistance development.

Innovation Solution

A novel therapeutic regimen using imidazolepiperazine KAF156, administered daily at doses of 200 mg to 1000 mg for up to 5 days, optionally combined with lumefantrine, to treat or prevent malaria, ensuring adequate parasiticidal serum levels for at least 6-7 days.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If artemisinin-based combination therapies are used to treat malaria, then treatment efficacy against sensitive strains is improved, but drug resistance develops leading to treatment failure

Engineering Contradiction:

Improvetreatment efficacyVSAvoiddrug resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a novel chemical compound with a different molecular structure (imidazolepiperazine scaffold) and mechanism of action compared to existing artemisinin-based therapies. This fundamental parameter change in the therapeutic agent enables activity against artemisinin-resistant Plasmodium falciparum strains while maintaining efficacy against sensitive strains, thereby resolving the contradiction between treatment reliability and drug resistance

Inventive Principle:

Principle #35Parameter changes

2Reliability

If standard antimalarial dosing regimens are used, then treatment coverage is sufficient, but treatment duration is lengthy leading to non-compliance

Engineering Contradiction:

Improvetreatment coverageVSAvoidtreatment duration

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent employs a higher single dose (500-1000 mg) of the imidazolepiperazine compound to achieve adequate parasiticidal levels more quickly. This partial or excessive action approach allows for a shortened treatment course of 3-5 days while maintaining sufficient treatment coverage, thereby resolving the contradiction between treatment reliability and treatment duration

Inventive Principle:

Principle #16Partial or excessive action

Solution Approach 2:

The dosing regimen utilizes periodic administration at extended intervals (every 12-24 hours) rather than frequent dosing. This periodic action maintains therapeutic levels throughout the shortened treatment course while improving patient compliance, thus resolving the contradiction between adequate treatment coverage and reduced treatment duration

Inventive Principle:

Principle #19Periodic action

3Reliability

If artemisinin derivatives are administered with high fat food to increase bioavailability, then drug absorption is improved, but treatment complexity increases

Engineering Contradiction:

ImprovebioavailabilityVSAvoidadministration simplicity

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent describes the imidazolepiperazine compound as having favorable pharmacokinetic properties with adequate oral bioavailability that does not require the complex administration conditions (high fat food) needed for artemisinin derivatives. This simplifies the administration process while maintaining reliable drug delivery, resolving the contradiction between bioavailability and ease of operation

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Data Source

PatentUS12616700B2Therapeutic regimen

Publication Date: 2026.05.05 NOVARTIS AG

AI summary

The present invention relates to dosing regimen of a new antimalarial drug, as monotherapy or combination therapy.